CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
simvastatindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00334542
NCT00334542Phase 2Completed
CompareCT.gov

A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jun 8, 2006·Updated Apr 3, 2019

In Brief

A Phase 2 clinical trial evaluating simvastatin for Breast Cancer. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin may keep cancer from coming back in women who are at high risk for a new breast cancer after undergoing surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cancer. PURPOSE: This phase II trial is studying how well simvastatin works in preventing a new breast cancer in women at high risk for a new breast cancer after undergoing surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 8, 2006
Enrollment StartMar 1, 2006
Primary CompletionJun 1, 2009
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.1 years ago

Interventions

simvastatindrug

24-28 weeks of simvastatin